Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative therapies operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these compounds enhance insulin release and reduce

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in th